Compositions and methods for treatment of Parkinson's disease: a patent evaluation of WO2011/102847A1

Expert Opin Ther Pat. 2012 Feb;22(2):181-4. doi: 10.1517/13543776.2012.655269. Epub 2012 Jan 18.

Abstract

Background: The application (WO2011/102847A1) deals with methods useful for the treatment of Parkinson's disease (PD).

Objective: It aims at producing mature and functional midbrain dopaminergic (mDA) neurons useful for the treatment of PD.

Methods: mDA neurons were produced from neural progenitor cells or stem cells by activating both the Wnt-Lmx1a/Lmx1b and the SHH-FoxA2 signaling pathways.

Results: The level of the proteins of these two synergic pathways is increased, as well as their biological activity.

Conclusion: The invention provides a method for treating or preventing PD by increasing the level of at least one protein involved in an autoregulatory pathway, which is fundamental during mDA neurons differentiation.

MeSH terms

  • Animals
  • Antiparkinson Agents / pharmacology*
  • Biological Assay*
  • Cells, Cultured
  • Dopaminergic Neurons / drug effects*
  • Dopaminergic Neurons / metabolism
  • Hedgehog Proteins / metabolism
  • Hepatocyte Nuclear Factor 3-beta / metabolism
  • Humans
  • LIM-Homeodomain Proteins / metabolism
  • Mesencephalon / drug effects*
  • Mesencephalon / metabolism
  • Neural Stem Cells / drug effects*
  • Neural Stem Cells / metabolism
  • Neurogenesis / drug effects*
  • Patents as Topic
  • Wnt Signaling Pathway / drug effects

Substances

  • Antiparkinson Agents
  • Hedgehog Proteins
  • LIM-Homeodomain Proteins
  • Hepatocyte Nuclear Factor 3-beta